Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
benmelstobart + anlotinib + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical Group
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
QL1706 + anlotinib + nab-paclitaxel is an investigational triple combination therapy being evaluated for the treatment of advanced solid tumors, specifically triple-negative breast cancer (TNBC). The regimen consists of benmelstobart (QL1706), a bispecific antibody targeting both PD-1 and CTLA-4; anlotinib, a multi-target tyrosine kinase inhibitor (TKI) that inhibits VEGFR, FGFR, PDGFR, and c-Kit to provide anti-angiogenic and anti-proliferative effects; and nab-paclitaxel, an albumin-bound formulation of the microtubule-stabilizing chemotherapy agent paclitaxel. This combination strategy aims to enhance anti-tumor activity by simultaneously stimulating the immune system, inhibiting tumor vascularization, and inducing cytotoxic cell death. It is currently being studied in the Phase II QUEEN-APPLE trial as a first-line treatment for advanced TNBC.
- Other names
- iparomlimab and tuvonralimab + anlotinib + nab-paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRA (Platelet-derived growth factor receptor alpha)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)CD274 (Programmed cell death protein 1 ligand 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on benmelstobart + anlotinib + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on benmelstobart + anlotinib + nab-paclitaxel.